drugset / Trial / NCT01378104
100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
Phase 4
Completed
178 enrolled
The Catholic University of Korea
Chungnam National University · collabHallym University Medical Center · collabInha University Hospital · collabInje University · collabKeimyung University · collabKonyang University Hospital · collabKyungpook National University Hospital · collabNational Health Insurance Service Ilsan Hospital · collabSoonchunhyang University Hospital · collabUlsan University Hospital · collabYonsei University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
1. Randomized controlled multicenter study 2. The response of reducing dose of peginterferon alfa-2a in Koreans with chronic hepatitis C genotype 1 3. IL28B polymorphism in Koreans with CHC
Timeline
- Start
- 2008-10
- Primary completion
- 2011-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 135 ug | — |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
Indications
No indication recorded.